Use of Medications for Erectile Dysfunction in the United States, 1996 Through 2001

Wysowski, Diane K.; Swann, Joslyn

doi:10.1097/01.ju.0000045707.96565.cd

Cited by 26 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar condition was observed in the USA where the number of prescriptions for alprostadil injection decreased by 33% from 1998 through 2001 4 and in the UK where the cost for managing ED in NHS the ICI occupied 26.6% in 1997 and became negligible in 2000. 5 A study in Italy demonstrated that men with ED who were switched from stable ICI therapy to sildenafil expressed greater overall treatment satisfaction, better ease of use, naturalness of Three treatment modalities for erectile dysfunction B-P Jiann et al erectile process, and intention to continue treatment with sildenafil.…”

Section: Discussionsupporting

confidence: 70%

“…A report showed the number of prescriptions of sildenafil increased 87% from 7.5 to 14 million from 1998 through 2001 in the USA. 4 The growing sales of sildenafil in Taiwan followed this trend too.…”

Section: Discussionmentioning

confidence: 97%

“…A study in the USA also showed that mean age of men who received prescriptions with sildenafil in 2001 were younger than that of those in 1998. 4 These indicated a global change that more younger men with ED were willing to seek treatment in the era of oral pharmacotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales

Jiann

Cao

2004

Int J Impot Res

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales

Jiann

Cao

2004

Int J Impot Res

View full text Add to dashboard Cite

“…22 In contrast, urologists constituted 91.1% of sildenafil prescribers at our institution in Taiwan. Since ED is associated with multiple factors, more than 40% of our subjects sustained various chronic diseases that required long-term medication and regular followup.…”

Section: Discussionmentioning

confidence: 99%

What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience

et al. 2003

View full text Add to dashboard Cite

We retrospectively assessed the clinical uses and results of sildenafil in the treatment of erectile dysfunction (ED) in daily clinical practice from a cohort of 1658 subjects at a multispeciality medical center from 1999 to 2001 through a chart review, mailed questionnaire and telephone interview. The overall follow-up rate was 77.8% (1290/1658). The mean age was 63.8 y and ED duration was 3.4 y, and 44.6% of them had one or more concomitant conditions. The mean score of the International Index of Erectile Function erectile function domain was 12.7 in 314 nonselective subjects, and 75% of them had moderate to severe ED. The average number of purchase-visits and tablets of sildenafil purchased was 2.27 and 10.8 per person, respectively, and the prescription refill rate was 58.6%. Urology accounts for 91.4% of the specialties of prescribers. The response rate was 72.0%, which was significantly lower in subjects with diabetes, ischemic heart disease and following radical pelvic surgery than those without. Subjects with psychogenic etiology had the highest response rate, while those following radical pelvic surgery the lowest. Of the nonresponders, 67% did not try the maximum dose of 100 mg and 71.1% bought no more than four tablets. Adverse events were reported in 20.1% of the subjects. No one discontinued the treatment because of the adverse events. Mortality occurred in 17 subjects and none was considered related to sildenafil use. In conclusion, sildenafil was effective and safe in the treatment of ED in clinical practice. Compared with clinical trials or prospective clinical practice based studies, lack of dose titration, less follow-up visits and inadequate attempts before giving up were the main shortfalls in daily practice.

show abstract

“…However, the introduction of sildenafil, a specific phoshodiesterase 5 inhibitor in 1998, as the first oral drug with proven efficacy and safety in the treatment of erectile dysfunction has changed dramatically the management of our patients [1]. Sildenafil prescriptions raised significantly while the use of intracavernosal injections and intraurethral alprostadil-that were the only approved pharmacotherapiesremained unchanged [2]. Later apomorphine-a central acting dopaminergic agonist-and last year, two new phosphodiesterase 5 inhibitors-tadalafil and vardenafil-expanded treatment options.…”

Section: Introductionmentioning

confidence: 99%

Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy

Hatzimouratidis

Hatzichristou

2004

EAU Update Series

View full text Add to dashboard Cite

Oral drug therapy is the first line treatment for erectile dysfunction. Efficacy of oral drugs does not exceed 70%, while drop-out rate is high. Therefore, salvage strategies and second/third line treatment options are necessary to restore erectile function in such patients. The article reviews currently available data and comment on key issues that urologists address on their every day clinical practice.In order to do so, a literature-based critical presentation on the current methodological problems on definition of treatment failure, treatment outcome assessment and alternative therapeutic options was made.Emphasis was given in identifying truly non-responders, as proper instructions for oral drug administration and psychosexual counselling may reverse a substantial number of non-responders to responders. Medication, clinical and patient/partner related issues have been identify that may lead to treatment failure. Treatment outcome assessment based not only on quality of erectile response, but also on side effects profile and patient satisfaction is recommended. Treatment options for truly non-responders include intracavernosal injections, combination therapies, and penile prosthesis. Management strategy however, must identify patient and partner needs and expectations and involve them in the decision-making. #

show abstract

Use of Medications for Erectile Dysfunction in the United States, 1996 Through 2001

Cited by 26 publications

References 12 publications

Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales

Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales

What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience

Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy

Contact Info

Product

Resources

About